sunwin mit guten aussichten 2007,2008

Ich versuchs mal hier.Bin in sunwin long.
Bei wo bin ich schon lange dabei,wie bei sunwin.Hier ist nichts los.
Überzeugt werde ich fakten hier einbringen.
Zum diskutieren ist jeder eingeladen.
Nur,die meinung aufzuzwingen,das liegt mir nicht.
Gruss
sunwinner

   

Prior to our acquisition of Sunwin Tech, effective February 1, 2004, Sunwin Tech acquired 80% of Qufu ("the Qufu Merger") from Shandong Shengwang Pharmaceutical Group Corporation ("Group Corporation"), a company controlled by Mr. Laiwang Zhang, our President and Chairman, in exchange for all the outstanding shares of Sunwin Tech\'s common stock. At the time of this merger the minority shareholders of Qufu included Shandong Shengwang Pharmaceutical Corporation Ltd. ("Corporation Ltd.") (17%) and Shandong Shengwang Group Corporation (2.5%) ("Shengwang Group"), both of which are controlled by Mr. Laiwang Zhang, our President and Chairman. The remaining minority shareholder, Qufu Veterinary Medicine Company, Ltd. ("Qufu Vet Ltd") (0.5%) was controlled by a Chinese state owned agency.

In July 2004 following the transaction with Sunwin Tech, we changed the name of our company from Network USA, Inc. to Sunwin International Neutraceuticals, Inc. ("Sunwin" or the "Company").

Subsequent to the Qufu Merger, the Shengwang Group acquired the 17% interest of Qufu owned by Corporation Ltd., and ultimately the Shengwang Group acquired the 0.5% Qufu interest owned by Qufu Vet Ltd,, after Qufu Vet Ltd. was dissolved. These events subsequent to the Qufu Merger, resulted in the Shengwang Group owning 20% of Qufu.

In February 2006, the Company acquired the remaining 20% of Qufu from Shandong Group in exchange for 5,000,000 shares of our common stock valued at $2,775,000. Our president and Chairman, Mr. Laiwang Zhang, is a control person of Shandong Group. Of the total purchase price, approximately $180,000 was allocated to consulting expenses paid to Mr. Zhang as it represented the difference between the purchase price and the valuation of the minority interest purchased.

Through our subsidiaries, we manufacture and sell neutraceutical products which can be classified into three main product groups including; stevioside, a 100% natural sweetener, veterinary medicines and animal feed additives, and traditional Chinese medicine formula extracts. All of our business and operations are located in the People\'s Republic of China.

The majority of our revenues are derived from our stevioside product, and our principal customers for this product are located in Asia, primarily China and Japan where stevioside is approved for use both as a food additive as well as a nutritional supplement.

This product group represented approximately 47% of our total revenues for fiscal 2006. China has grown into the world\'s largest exporting company of stevioside, with volume exceeding 80% of the world\'s supply. We believe that we are one of the top three companies in China manufacturing stevioside.

We also manufacture and sell a comprehensive line of veterinary medicines including seven series of more than 200 products. These veterinary medicines include traditional Chinese medicine as well as western medicines, feed additives, feeds and antibiotics.

We are an advocate of developing animal medicines from Chinese herbs, especially antivirus and feed additives. We are concentrating our efforts in this product category on developing and producing medicines which are relevant to the needs of the animal stock industry in the PRC, and developing special veterinary medicines made from pure traditional Chinese medicines or combining traditional Chinese medicine with Western medicine. This product group represented approximately 26% of our total revenues for fiscal 2006. Our last product group includes the manufacture and sale of traditional Chinese medicines formula extracts that are used in products made for use by both humans and animals. This product group represented approximately 27% of our total revenues for fiscal 2006.

Our ability to significantly increase our revenues in any of these groups faces a number of challenges. In addition to the existing laws which limit the sale of stevioside to Western countries, we face competition in the manufacture and sale of stevioside. There are approximately 30 stevioside manufacturers in China, with only approximately 10 companies operating on a continuing basis. Our other two product groups operate in highly competitive environments. We estimate that there are more than 5,000 companies in China selling animal medicines and more than 200 companies in China that produce Chinese traditional medicines and extracts and refined chemical products. The sale of our products in these two product groups are concentrated on domestic customers therefore our ability to expand our revenues in these product groups is limited to a certain extent by economic conditions in the PRC. In addition, since we are dependent upon raw materials which are harvested and farmed, our ability to produce our products and compete in our markets is also subject to risks including weather and similar events which may reduce the amount of raw materials we are able to purchase from farmers as well as increased competition or market pressure which may result in reduced prices for our products. Our ability, however, to expand our revenues from the sale of stevioside is limited as the product is not approved for use as a food additive in most Western countries, including the United States, Canada and the European Union. In these countries forms of stevioside can be marketed and sold as a nutritional supplement. In an effort to increase our competitive position within our market segment, we have built an additional stevioside manufacturing line in order to expand our stevioside production, upgraded our exiting manufacturing stevioside line, and relocated to a larger facility. In addition, during fiscal year 2005 and the first three quarters of fiscal year 2006 we were involved in reconstructing an additional veterinary production line into a new building which was put into full production in December 2005.

Through April 30, 2006, we have invested an aggregate of approximately $1,967,667 to be used for leasehold improvements and equipment towards the additional veterinary medicine manufacturing line and $1,214,777 towards the new stevioside facility.

Even though we are a U.S. company, because all of our operations are located in the PRC, we face certain risks associated with doing business in that country. These risks include risks associated with the ongoing transition from state business ownership to privatization, operating in a cash-based economy, various government policies, unexpected changes in regulatory requirements, export restrictions, tariffs and other trade barriers, challenges in staffing and managing operations in a communist country, differences in technology standards, employment laws and business practices, longer payment cycles and problems in collecting accounts receivable, changes in currency exchange rates and currency exchange controls. We are unable to control the vast majority of these risks associated both with our operations and the country in which they are located and these risks could result in significant declines in our revenues and adversely affect our ability to continue as a going concern.

Foreign Exchange Considerations

Since revenues from our operations in the PRC accounted for 100% of our net revenues for fiscal 2006 and fiscal 2005, how we report net revenues from our PRC-based operations is of particular importance to understanding our financial statements. Transactions and balances originally denominated in U.S. dollars are presented at their original amounts. Transactions and balances in other currencies are converted into U.S. dollars in accordance with Statement of Financial Accounting Standards (SFAS) No. 52,"Foreign Currency Translation," and are included in determining net income or loss. For foreign operations with the local currency as the functional currency, assets and liabilities are translated from the local currencies into U.S. dollars at the prevailing exchange rate on the respective balance sheet date.

Revenues and expenses are translated at weighted average exchange rates for the period to approximate translation at the exchange rates prevailing at the dates those elements are recognized in the financial statements. Translation adjustments resulting from the process of translating the local currency financial statements into U.S. dollars are included in determining comprehensive loss.

The functional currency of our Chinese subsidiaries is the local currency or the Chinese dollar called the Renminbi ("RMB"). The financial statements of our subsidiaries are translated to U.S. dollars using year-end rates of exchange for assets and liabilities, and average rates of exchange for the period for revenues, costs, and expenses. Net gains and losses resulting from foreign exchange transactions are included in the consolidated statements of operations and were not material during the periods presented. The cumulative translation adjustment and effect of exchange rate changes on cash at April 30, 2006 was $227,631. Until 1994, the Renminbi experienced a gradual but significant devaluation against most major currencies, including the U.S. dollar. There was a significant devaluation of the Renminbi on January 1, 1994 in connection with the replacement of the dual exchange rate system with a unified managed floating rate foreign exchange system. Since 1994, the value of the Renminbi relative to the U.S. dollar has remained stable; appreciating slightly against the U.S. dollar. Countries, including the United States, have historically argued that the Renminbi is artificially undervalued due to China\'s current monetary policies and have pressured China to allow the Renminbi to float freely in world markets. On July 21, 2005, the PRC announced that the Renminbi would be pegged to a basket of currencies rather than just tied to a fixed exchange rate to the U.S. dollar. It also increased the value of its currency 2% higher against the U.S. dollar, effective immediately

If any devaluation of the Renminbi were to occur in the future, returns on our operations in China, which are expected to be in the form of Renminbi, will be negatively impacted upon conversion to U.S. dollars. Although we attempt to have most future payments, mainly repayments of loans and capital contributions denominated in U.S. dollars, if any increase in the value of the Renminbi were to occur in the future, our product sales in China and in other countries may be negatively affected.

Critical Accounting Policies

The discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

A summary of significant accounting policies is included in Note 1 to the audited consolidated financial statements included in this annual report. Management believes that the application of these policies on a consistent basis enables us to provide useful and reliable financial information about the company\'s operating results and financial condition.

We record property and equipment at cost. Depreciation and amortization are provided using the straight-line method over the estimated economic lives of the assets, which are from five to 20 years. Expenditures for major renewals and improvements which extend the useful lives of property and equipment are capitalized. Expenditures for maintenance and repairs are charged to expense as incurred. We review the carrying value of long-lived assets for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets is measured by a comparison of its carrying amount to the undiscounted cash flows that the asset or asset group is expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the property, if any, exceeds its fair market value.

We account for stock options issued to employees in accordance with the provisions of Accounting Principles Board ("APB") Opinion No. 25, "Accounting for Stock Issued to Employees", and related interpretations. As such, compensation cost is measured on the date of grant as the excess of the current market price of the underlying stock over the exercise price. Such compensation amounts, if any, are amortized over the respective vesting periods of the option grant. We adopted the disclosure provisions of SFAS No. 123, "Accounting for Stock-Based Compensation" and SFAS 148, "Accounting for Stock-Based Compensation- -Transition and Disclosure", which permits entities to provide pro forma net income (loss) and pro forma earnings (loss) per share disclosures for employee stock option grants as if the fair-valued based method defined in SFAS No. 123 had been applied. We account for stock options and stock issued to non-employees for goods or services in accordance with the fair value method of SFAS 123. In December 2004, the FASB issued FASB Statement No. 123R, "Share-Based Payment, an Amendment of FASB Statement No. 123" ("FAS No. 123R"). FAS No. 123R requires companies to recognize in the statement of operations the grant- date fair value of stock options and other equity-based compensation issued to employees. We adopted FAS No.123R in the second quarter of fiscal year 2006.

RESULTS OF OPERATIONS

YEAR ENDED APRIL 30, 2006 AS COMPARED TO YEAR ENDED APRIL 30, 2005

Internally we identify our products in three product groups, stevioside, traditional Chinese medicine formula extracts and veterinary medicines. For accounting purposes, we report two segments which include stevioside as one segment and traditional Chinese medicine extracts and veterinary medicine products as the second segment.

Revenues

For the year ended April 30, 2006, our revenues were $15,490,013 as compared to $12,114,006 for the year ended April 30, 2005, an increase of $3,376,007 or approximately 27.9%. For fiscal 2006, revenues from our stevioside segment represented approximately 47% of our net revenues and revenues from our traditional Chinese medicine extracts and veterinary medicine segment represented approximately 53% of our total net revenues. We attribute our overall increase in net revenues to an increase in revenues from each of our product lines;

o revenues from the sale of our natural sweetener, stevioside increased $1,660,953,
o revenues from the manufacture and sale of our traditional Chinese medicine increased $796,425, and
o revenues from our veterinary medicine increased $918,629

The increase in the sale of our natural sweetener, stevioside, was due to the completion of our manufacturing equipment upgrade. Our revenues related to the manufacture and sale of stevioside increased from approximately $5,540,567 to $7,201,520, a 30% increase from April 30, 2005 to April 30, 2006. In September 2005 we commenced operations on our new manufacturing line; the facility became fully operational in November 2005. The new facility improves the quality of our stevioside and allows to acquire a larger market share. We manufactured 107 tons of stevioside and resold 123 tons during fiscal year 2006. We anticipate manufacturing 300 tons of stevioside during fiscal year 2007. We believe that the market for stevioside remains strong as we continue to witness growing demand for the product from consumers based in Japan resulting in increased exports to Japan. In order to ensure we have a sufficient supply of raw materials for production next year, we have prepaid farmers to harvest stevioside leaves, which increased our prepaid expenses by approximately $117,593 on our consolidated balance sheet as of April 30, 2006.

Our revenues related to traditional Chinese medicine increased from approximately $3,420,000 to $4,217,000, a 23% increase from April 30, 2005 to April 30, 2006. Our gross profit rate has grown from 39% to 41% from April 30, 2005 to April 30, 2006 on this product line due to the introduction of new products and improved sales. The Chinese central government issued a new rule for the Chinese Medicine industry that all manufactures should satisfy good manufacturing practices (GMP) standards in their production process before December 31, 2005. We completed our manufacturing equipment upgrade and as a result currently satisfy the GMP standards requirements in December 2005. As a result of these new regulations, we believe there was a significant market vacancy left by competitors who did not conform to the heightened standards. We believe that the new rules implemented by the central government of China helped us to establish a reputation within this field and acquire a larger market share. In December 2005, we completed the expansion and upgrade of our traditional Chinese medicine production facility and following this upgrade we launched five additional traditional Chinese medicine products. In January 2006, we introduced new products into the market and established a new products series, natural dietary health food. We expect to achieve growth in our traditional Chinese medicine division in our fiscal 2007.

Our revenues related to veterinary medicine increased from approximately $3,153,000 to $4,072,000, a 29% increase from April 30, 2005 to April 30, 2006. Furthermore our gross profit has grown from approximately $1,007,319 to $1,357,270, an approximate 35% increase from April 30,2005 to April 30, 2006 due to the introduction of new products and improved sales skills. Similar to the rules which effected our production of traditional Chinese medicine extracts described above, the Chinese central government also issued a new rule for the veterinary industry mandating that all manufacturers satisfy GMP standards in their production process on or before December 31, 2005. We completed the construction and finished the inspection process of our facilities in December 2005. As a result of these new regulations, we also believe a significant market vacancy was left by competitors who did not conform to the heightened standards and that this void enabled us to acquire a larger market share. From January 2006, we introduced five new products into the market. We expect to achieve growth in our veterinary medicine division in our fiscal 2007.

In December 2005, Sunwin has completed the expansion and upgrade of the veterinary medicine production facility. As a result, Sunwin launched 5 additional veterinary medicine products; Amoxicillin, Cephalosporium, Ampicillin, 4 mn iu sodium oxacillin, and penbritin. These five new products are employed as antiviral agents, to combat fever and treat respiratory tract infections. In fiscal 2006, these new products accounted for approximately 1.71% of revenue.

Cost of Sales and Gross Profit

For the year ended April 30, 2006, cost of sales amounted to $10,865,917 or 70% of net revenues as compared to cost of sales of $8,378,838 or 69% of net revenues for the year ended April 30, 2005, a percentage increase of 1%. Gross profit for the year ended April 30, 2006 was $4,624,096 or 30% of revenues, as compared to $3,735,168, or 31% of revenues for the year ended April 30, 2005.

Total Operating Expenses

Our total operating expenses increased for the year ended April 30, 2006 from the year ended April 30, 2005. Total operating expenses were $2,195,955 for the year ended April 30, 2006 while total operating expenses were $2,110,340 for the year ended April 30, 2005 an increase of $85,625, or approximately 4.1%. Included in this increase were:

o For the year ended April 30, 2006, we recorded non-cash compensation expense of $569,581 as compared to $220,000 for the year ended April 30, 2005, an increase of $349,581 or 159%. This amount represented the value of shares of our common stock we issued as compensation for consulting services and professional services being rendered to us. While we anticipate that we will enter into similar agreements during fiscal 2007, we cannot predict the amount of expense which will be attributable to such agreements;

o For the year ended April 30, 2006, selling expenses amounted to $615,348 compared to $923,114 for the year ended April 30, 2005 a decrease of $307,766 or 33%. For the year ended April 30, 2006 we experienced an increase in commission expenses of approximately $173,000, increased marketing expenses of approximately $53,000 increased shipping and freight costs of approximately $84,000 and an overall increase in other selling expenses of $22,300. These increases were offset by bad debt recovery of approximately $640,090 from the collection of previously reserved receivable balances; and

o For the year ended April 30, 2006, general and administrative expenses were $ 1,011,026 as compared to $967,226 for the year ended April 30, 2005, an increase of $43,800 or 4.5%. Travel related expenses included in the general and administrative costs increased from $25,000 for fiscal year 2005 to $110,000 for fiscal year 2006 which reflects expenses associated with our efforts to expand distribution of stevioside into North America. As well, we recognized increased general and administrative costs which are primarily due to the increase in our operations. As a result of our manufacturing upgrades, we realized a decrease in repairs, maintenance and retooling expenses. The repairs and maintenance expense amounted to $8,752 for the year ended April 30, 2006, a decrease from the $19,374 incurred for the year ending April 30, 2005. We expect expenditures for repairs, maintenance and facility upgrades to decrease in future periods as much of our upgrade and renovation projects was completed in December 2005. For the year ended April 30, 2006 we experienced an increase in management fees from approximately $44,000 in fiscal 2005 to approximately $123,000 in fiscal 2006, an increase of approximately $79,000. Shandong Shengwang Pharmaceutical Corporation, Limited, a company controlled by Mr. Zhang, our CEO, provides management services to us which includes costs and services related to housing provided to certain of our non-management employees, government mandatory insurance for our employees and rent for our principal offices and the research and development facilities we use. We do not have a contract with Shandong Shengwang Pharmaceutical Corporation, Limited and the amount of annual management fee is subject to increase at Mr. Zhang\'s discretion. We also reported an overall increase in other general and administrative expenses of approximately $20,700 associated with an increase in operations; this increase was offset by a decrease of approximately $56,200 in research and development expenses. Finally, we reported a decrease in advertising expenses for fiscal 2006 of approximately $41,000, from $212,865 in fiscal 2005 to $171,896 in fiscal 2006. This decrease is reflects a reduction in funds spent on advertising our veterinary medicines in fiscal 2006. Sunwin incurred a decrease in advertising costs related to its veterinary medicine division. Industry regulations adopted by the central government regarding good manufacturing process ("GMP") have limited competition in the industry. As such the Company has reduced their advertising expenditures in the veterinary medicine department.

o Legal and accounting fees increased to approximately $62,000 in Fiscal 2006 from approximately $53,000 in Fiscal 2005. This increase is primarily attributable to costs associated with our annual audit and a registration statement we filed during Fiscal 2006 with the SEC and other required filings with the SEC. During fiscal 2007 we anticipate further increases in legal and accounting fees associated with our continued compliance with provisions of the Sarbanes-Oxley Act of 2002, including new provisions which will phase in during fiscal 2007.

Total Other Income (Expense)

For fiscal 2006 we reported total other income of $68,337 as compared to total other expense of $2,960 for fiscal 2005. This change included:

o Other income amounted to $103,675 for the year ended April 30, 2006 as compared to other income of $59,094 for the year ended April 30, 2005. Other income for the year ended April 30, 2006 was associated with income recognized from the over accrual of value-added taxes on certain of our animal medicine products which had not been assessed to our customers. Certain of our animal medicine products are not subject to value added taxes. However until we received notification of such position from the respective tax authority, we had accrued additional value added taxes. Upon notification from the tax authority, the accrued taxes were recorded as other income for the period ending April 30, 2006.

o Interest expense was $35,338 in Fiscal 2006 as compared to $62,054 in Fiscal 2005. Interest expense for the year ended April 30, 2006 and 2005 was associated with our borrowings. The amount of loans payable was $255,487 and $592,541 and for Fiscal 2006 and Fiscal 2005 respectively, a decrease of $337,054, accordingly, the interest expense decreased. Given our current cash flow from our operations, we expect we are able to meet the obligation of the debt services from our existing working capital.

Our income before minority interest was $3,020,959 for the year ended April 30, 2006 as compared to $1,108,495 for the year ended April 30, 2005, an increase of $1,912,464 or 172.5%. On February 7, 2006, we acquired the remaining 20% of Qufu and, as a result, Qufu is now our wholly-owned subsidiary effective on February 1, 2006. The acquisition of the remaining 20% of Qufu was a non cash transaction, whereby we issued 5,000,000 shares of our common stock to acquire the remaining 20% of Qufu.

For the year ended April 30, 2006, we reported a minority interest in income of subsidiary (Qufu) of $591,145 as compared to $279,381 for the year ended April 30, 2005. The minority interest for Fiscal 2006 represents the minority interest\'s proportional share of Qufu\'s net income up until the date we acquired the minority interest ownership in Qufu.

As a result of these factors, we reported net income of $2,429,814 or $.05 per share for the year ended April 30, 2006 as compared to net income of $829,114 or $.02 per share for the year ended April 30, 2005.

LIQUIDITY AND CAPITAL RESOURCES

At April 30, 2005, we had working capital of $8,908,577 and cash and cash equivalents of $5,433,691. At April 30, 2006, our cash position by geographic area is as follow

Fiskaljahr 2006
Umsatz= 15,49 Mio$
NetIncome= 2,429 Mio$ ( 0,05$/Share)

Cash zum 30.April 2006
5,433 Mio$

Umsatzaufteilung:
NaturalSweeter 7,20 Mio$
ChineseMedicine 4,22 Mio$
VeterinaryMedicine 4,07Mio$


FJ 2006 (Umsätze)
Q1= 3,171 Mio$
Q2= 4,053 Mio$
Q3= 3,842 Mio$
Q4= 4,424 Mio$

FJ 2006 (Gewinne)
Q1= 0,255 Mio$
Q2= 0,899 Mio$
Q3= 0,871 Mio$
Q4= 0,404 Mio$

Update maydornreport

vom 10.8.06


Sunwin: Gute Zahlen, prima Ausblick
Nach langer Wartezeit hat unser Depot-
wert Sunwin gestern nach Börsenschluss
endlich die Zahlen für das am 31. April
beendete Geschäftsjahr vorgelegt. Letzt-
lich entsprachen diese ziemlich exakt un-
seren Erwartungen. Der Umsatz legte um
28 Prozent auf 15,5 Millionen Dollar zu,
wir hatten mit 16 Millionen Dollar gerech-
net. Der Gewinn pro Aktie erreichte 0,05
Dollar pro Aktie. Rechnet man die Zahl-
ungen an Mitarbeiter mit Aktien und
Optionen heraus, dann sind es sogar 0,06
Dollar Gewinn pro Aktie und damit exakt
so viel wie erwartet. Aber viel wichtiger
als das Ergebnis der Vergangenheit ist
der Blick in die Zukunft. Und schließlich
läuft das neue Geschäftsjahr ja schon seit
dem 1. Mai. Sunwin hat in den vergange-
nen Monaten die Produktionskapazitäten
deutlich ausgeweitet und überdies mit der
Vermarktung seiner Produkte in Nord-
amerika begonnen. Bei einem erfolgrei-
chen Verlauf ist für das laufende Ge-
schäftsjahr mit einem deutlichen Umsatz-
und Gewinnsprung zu rechnen. Ich bleibe
bei meiner Schätzung von 0,14 Dollar
Gewinn bei Umsätzen von 25 Millionen
Dollar für das laufende Jahr. Beim derzei-
tigen Aktienkurs von 0,88 Dollar ist Sun-
win derzeit also mit einem 2007er-KGV
von 6,3 bewertet. Bis auf Commercepla-
net fällt mir derzeit kaum eine ähnlich
wachstumsstarke Aktie ein, die günstiger
bewertet ist.

Fiskaljahr 2006 (1.Mai 2005-30.April 2006)

Gesamtumsatz= 15,49Mio$
Q1/2006 Gesamtumsatz= 3,172 Mio$
Q2/2006 Gesamtumsatz= 4,051 Mio$
Q3/2006 Gesamtumsatz= 3,843 Mio$
Q4/2006 Gesamtumsatz= 4,424 Mio$


Umsätze von NaturalSweetener
Q1= 1,315 Mio$
Q2= 1,549 Mio$ = +18% zum Vorquartal
Q3= 1,579 Mio$ = +2% zum Vorqurtal
Q4= 2,758 Mio$ = +75% zum Vorquartal

Umätze von ChineseMedicine
Q1= 1,014 Mio$
Q2= 1,168 Mio$ = +15% zum Vorquartal
Q3= 1,166 Mio$ = -0% zum Vorquartal
Q4= 0,869 Mio$ = -25% zum Vorquartal

Umsätze von VeterinaryMedicine
Q1= 0,843 Mio$
Q2= 1,334 Mio$ = +58% zum Vorquartal
Q3= 1,098 Mio$ = -18% zum Vorquartal
Q4= 0,797 Mio$ = -27% zum Vorquartal

Global Biotech Investing
Nr. 15 vom 14. August 2006
Von unseren Empfehlungen der zweiten und dritten Reihe legte Top-Empfehlung SUNWIN INTERNATIONAL neue Geschäftszahlen auf den Tisch! Das Unternehmen gab vergangenen Mittwoch seine Ergebnisse für das Fiskaljahr 2006 bekannt, das am 30. April zu Ende ging: SUNWIN INTERNATIONAL steigerte seinen Umsatz gegenüber dem Fiskaljahr 2005 von USD 12.1 Mio. auf USD 15.5 Mio., 47% des Umsatzes erzielte man dabei mit dem natürlichen und kalorienfreien
Süßungsmittel Stevioside. Bedenken Sie aber bitte: Vergangenen September hatte das Unternehmen erst seine Produktionskapazitäten durch eine Übernahme erweitert, die neuen Produktionsstätten waren erst ab November voll einsatzfähig und konnten daher nur ein halbes Jahr zum Ergebnis beitragen. Insgesamt produzierte
SUNWIN INTERNATIONAL im vergangenen Jahr 107 Tonnen des Süßungsmittels, während man aber 123 Tonnen verkaufte und damit an die Lagerbestände gehen musste. Nun dürfte die Nachfrage aber aus der Produktion befriedigt werden können, denn: Im laufenden Jahr sollen nun 300 Tonnen Stevioside produziert werden! Unter dem
Strich konnte man den Nettogewinn von USD 829`000 auf USD 2.43 Mio. verdreifachen, was einem Gewinn je Aktie von 5 Cents entspricht. Damit liegt SUNWIN INTERNATIONAL voll in den Planungen, per 2008 einen Gewinn zwischen USD 8 Mio. und USD 10 Mio. einzufahren. Auch wenn Sie seit unserer Erstempfehlung vergangenen November zu Kursen um USD 0.20 Ihren Einsatz aktuell mehr als vervierfacht haben, bekommen Sie den Titel aktuell noch immer fast geschenkt, denn: Bei einer momentanen Market-Cap von USD 57 Mio. wird die Aktie also mit einem KGV zwischen 5.7 und 7.1 auf Basis der nächstjährigen Gewinne verramscht, wir stufen den Titel weiterhin mit einem klaren „Strong Buy“ ein! (WKN A0D 9SL, Kurs aktuell EUR 0.67, Reuters SUWN)

Dutton Associates Announces Investment Opinion: Sunwin International Neutraceuticals Strong Speculative Buy In Update Coverage By Dutton Associates
Monday August 21, 12:00 pm ET


EL DORADO HILLS, Calif.--(BUSINESS WIRE)--Aug. 21, 2006--Dutton Associates continues its coverage of Sunwin International Pharmaceuticals (OTCBB:SUWN - News) reiterating a Strong Speculative Buy rating and a price target of $1.85. The 11-page report by Dutton senior analyst Stanley Ng is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Reuters, Knobias, and other leading financial portals.
ADVERTISEMENT


Sunwin\'s recently announced record high revenue and net income for FY2006, amid a weaker-than-expected fourth quarter earnings. Higher expenses related to the promotion of new TCM and veterinary products, stock-based compensation for hiring professional services to market and distribute natural sweetener products in the United States, and traveling expenses for the road show in the United States to promote business were the culprits on dragging down earnings in the fourth quarter. Given that these expenses are either non-recurrent or positive for driving future sales, our positive view on Sunwin\'s earnings outlook remains intact. For prudence, we have slightly adjusted downward our revenue projections for Chinese medicines and animal medicines but maintain our revenue projections for natural sweetener for the coming two years. Meanwhile, we have reduced our assumptions for certain expenses, such as repairs and maintenance due to more efficient productions from the newly built/upgraded facilities and lower advertising expenses for veterinary medicines due to reduced market competition as competitors that did not conform to the good manufacturing process (GMP) requirement gradually leave the market. Introduction of new TCM and veterinary medicine and higher percentage of self-manufactured natural sweetener sales should help lift margins. We are modestly adjusting our price/earnings multiple that we are applying to Sunwin from 25 to 23. Based on the revised EPS forecast of $0.081, our 12-month target price of $1.85 per share remains unchanged.



www.jmdutton.com/research/suwn/reports/suwn_report_082106.pdf

aus pennystockraketen


Bei Sunwin handelt es sich um ein aufstrebendes chinesisches Unternehmen, welches mit Steviosid über ein Hauptprodukt verfügt, das gerade dabei ist, den weltweiten Süßmittelmarkt zu revolutionieren. Steviosid als Molekül der populären Steviapflanze wirkt als völlig natürlicher Süßstoff und ist vollkommen frei von
Nebenwirkungen. Dieser Zuckerersatz ist aufgrund seiner einzigartigen Vorteile dem bei uns bekannten raffinierten
Zucker turmhoch überlegen. Sunwin will im kommenden Jahr bereits eine Gesamtproduktion von 500 Tonnen Stevia erreichen; für 2008 sind gar mehr als 1.000 Tonnen geplant. Der Gewinn per 2008 soll
sich auf bis zu 10 Millionen Dollar belaufen. Die Chancen für eine derart rasante Produktions- und Gewinnausweitung
stehen mehr als gut: Stevia hat nicht nur in Japan die Hälfte des gesamten Süßmittelmarktes erobert; der pflanzliche Süßstoff befindet sich auch in China gewaltig auf dem Vormarsch. Damit nicht genug:
Auch in den USA scheint der Durchbruch von Sunwin nicht mehr aufzuhalten sein. Selbst in Kanada hat das Management von Sunwin jetzt zugeschlagen: Dort gründete man das Tochterunternehmen Sunwin Pharmaceuticals, um auch vom explosiv wachsenden kanadischen
Markt profitieren zu können. Stevia ist unter anderem deshalb ein Renner, weil es über einen 30mal so hohen Ernteertrag wie der überaus ungesunde raffinierte Zucker verfügt. Das ist noch nicht alles: Stevia hat darüber hinaus keine Kalorien, ist untoxisch, beugt körperlicher und emotionaler Erschöpfung vor und bewirkt eine Stimmungsaufhellung. Zudem harmonisiert es den Blutdruck
und hilft bei Infektionen, Rheuma und Entzündungen.
Fazit: Sunwin (WKN A0D9SL; aktueller Kurs: 0,62 Euro) steht am Beginn einer Erfolgsgeschichte. Die bärenstarke Stellung im TCM-Sektor (= traditionelle chinesische Medizin), die Phantasie im Vogelgrippe- Sektor (dort verfügt man mit Hypericin über ein wirksames „Hammer“-Produkt), die günstigen Kennzahlen
(KGV unter 10!) sowie das hyperschnelle Wachstum sprechen für die aufstrebende Gesellschaft. Da die Firma noch sehr jung und überaus klein ist, sollten sich nur hochspekulativ ausgerichtete Anleger in Sunwin engagieren. Auf aktuellem Niveau empfiehlt sich eine erste Anfangsposition, da die Bodenbildung um 0,60 Euro gelingen sollte.

Es fehlt ab und zu ein n bei aussichten,tut mir sehr leid.
Ein schönes wochenende,für alle
Möge ein informativer thread daraus entstehen.


Dieser Thread wurde 13 mal gelesen und wurde mit -1 Punkt bewertet.  


Habs gesehen.
All mein wissen der letzten zeit hab ich hier preisgegeben.
Auf weiterliegendes kann man verzichten,sind schon andere threads hier.
Zu fragen,gibt es antworten.
          SW
       

nauticus,versteh ich nicht,warum falsch.
Wenn ich hier irgentwas nicht richtig beachtet habe,nur zu,bin bei ariva neu.

sunwin mit guten aussichte 2007,2008





Das Fiskaljahr 2007 fing bei s1n am 1.5.2006 an.
Die letzten zahlen sind vom FK 2006.
Also werden im september die zahlen 2007;Quartal 01 erwartet.

SW

Es ist ja auch schon spät
Deswegen führ ich noch einige adressen zur information an.
Das sunwin 3 Standbeine hat,müsste klar sein
1.Stevia
2.TCM;Traditionelle Chinesische Medizin
3.Veteränärmedizinische Produkte

Information auf
www.sunwin.biz

Zu stevia

www.freestevia.de
www.cookingwithstevia.com
 

Auch ohne antwort weiss ich wohl,was gemeint ist.
Werde erstmal nichts mehr einstellen,warte auf antworten.

Die Blätter von Stevia rebaudiana, sowie die daraus isolierten Steviolglykoside bieten im Vergleich mit anderen Süßmitteln für den Verbraucher viele markante Vorteile:

Stevia / Steviolglykoside sind keine chemischen, sondern rein natürliche Produkt e

enthalten absolut keine Kalorien

die Blätter können in ihrem Ursprungszustand verwendet werden

dank ihrer sehr großen Süßkraft, ist ein geringer Verbrauch erforderlich

die Pflanze ist nicht toxisch

sowohl Blätter als auch die Steviolglykoside können gekocht werden

beständig bis zu einer Erhitzung von 200°C

keine Gärung

als Süßungsmittel bei Diabetes, Neurodermitis, Zucker- und Sorbitunverträglichkeit bestens geeignet

geschmacksverbessernd

klinisch getestet

ideale Süße auch für Kinder, macht nicht abhängig, fördert kein Karies
Stevia-Blätter und Steviolglykoside haben mit dem Zucker nur den süßen Geschmack gemein. Die Blätter, wie auch die isolierten Steviolglykoside haben keine Kalorien und beeinflussen nicht den Blutzuckerspiegel.
(Dr. med. Johann Christian Huber: „Der Einfluß der Süßstoffe Acesulfam-K und Steviosid auf die Sekretion gastrointestinaler Hormone beim Menschen“, Ulm, Univ., Diss., 1995)



Der Einfluss von verschiedenen Süßungsmitteln auf den Blutzuckerspiegel und die Insulinproduktion.

Die Süßkraft der getrockneten Stevia-Blätter entspricht etwa dem 15 bis 30 fachen Wert unseres Zuckers.
Stevia rebaudiana wird nicht nur traditionell von den Einwohnern Südamerikas als Süßungsmittel verwendet, sondern feiert seit einigen Jahrzehnten einen waren Siegeszug in den Industrieländern. Größter Verbraucher von Stevia ist Japan, wo bereits 1954 mit dem Anbau begonnen wurde. Als die japanische Regierung 1969, wegen gesundheitlicher Risiken, den Verkauf von synthetischen Süßstoffen verbot, stieg dort der Verbrauch von Stevia extrem an und hat inzwischen einen Marktanteil von über 40%. Sie finden heute Stevia in japanischen Fertignahrungen, in eingelegten Meeresfrüchten, Süßigkeiten, Kaugummi, Sojasauce, ebenso in Getränken wie der japanischen Version von Cola-Light.

Es sind sehr viele wissenschaftliche Studien zu Stevia durchgeführt worden. So wurde unter Anderem der Einfluss auf den Blutzuckerspiegel, den Blutdruck und die Fruchtbarkeit untersucht. Nach objektiver Sichtung und Beurteilung dieser Unmengen von Daten, können wir heute davon ausgehen, dass Stevia das natürlichste, sicherste und gesündeste Süßungsmittel auf dieser Erde ist. Zudem hat 2004 JECFA, eine Arbeitsgruppe der WHO, die gesundheitliche Unbedenklichkeit von Stevia rebaudiana und den daraus hergestellten Auszügen bestätigt.

quelle www.freestevia.de  

könntest du bitte deien Schwarzen auch begründen?

lg
o

sunwinner, Du schreibst, dass Du "Bei wo bin ich schon lange dabei,wie bei ....." seist.
Da ich auch öffters dort  unterwegs bin, und niemanden mit dem Namen bez.ID sunwinner
dort kenne, habe ich meine Zweifel an Dir. Sorry!!
Aber habe mitlerweile leider zu viele Basher bez. Pusher gennen lernen müssen.

Außerdem gibt es schon Thread zu Sunwin!!!

Also wenn Du schon "neu" hier bist, dann bitte auch vorher informieren.

Olly,meine wo id schreib ich nicht hier hin,da ich es nicht mache,vergessen wir es.Ein fehler von mir darauf hinzuweisen.
Schau Dir mal die Anderen an,es gibt mehrere Threads hier,in meinem steckt viel Information,das in der kurzen Zeit.Vieleicht zuviel auf einmal.
Könnt es weiterführen,soll kein Monolog sein.
Bin selber bei sunwin seit Anfang des Jahres drinn.
Da ich hier nicht als Pusher gelten will,halt ich mich demnächt zurück.Eine neue News werd ich natürlich sofort einstellen.
Ich hab auch bisher den Jahresabschluss und Emfehlungen aus Böersenbriefen eingestellt,auch aus Pusherblättchen.
Du wirst von mir nie erleben,das ich zum Kaufen auffordere.
Das einzige ist in dem Threadtitel zu erkennen,halte es für ein gutes Langfristinvest.
Die Shorts kamen  auch bestimmt nicht zu kurz.

Vielleicht kommt unter Interressierten und Anderen eine Diskusion auf.

 

Lassen wir das mal mit der wo ID im Raum stehen.

Ich kenne die anderen Threads von Sunwin sehr gut. Daher muss ich Dir auch
wiedersprechen. Denn auch dort stehen viele informative Dinge zu Sunwin,
geparrt mit den persönlichen Meinnungen der einzelnen User.
Denn genau das macht m.M. nach einen guten Threads erst aus.
Daher bleibe ich dabei, und sage die vorhandenen Threads reichen aus.

Was ich Dir eigendlich auch nur sagen wollte ist, das jeder neue Teilnehmer hier im
Board willkommen ist.
Aber wenn man schon neu hier ist sollte man sich vieleicht zu Anfang erst einmal
ausgibig einlesen. Auch das ist nur meine Meinung.

Ich selber bin ebenfalls "dick" in Sunwin infestiert und bin mir sehr sicher das ich, wir,  mit
dem Wert noch viel Freude haben werden.
Ob das nun long oder short ist, kann ich nicht so gut beurteilen.

Allen viel Erfolg

bei ariva.

greetz joker

Warum nicht ein neuer thread.
Zumindest wecke ich wieder ein bischen aufmerksamkeit.
Eingelesen hab ich mich genug,auch hier in den threads.

Auch dir viel Erfolg

 

Gut recherschiert.Was das heist,mein geheimniss,habs schnell vergessen.
Was ist ein fg,hoffentlich nichts unanständiges?

allen ernstes geglaubt,das dich hier keiner identifiziert?;-))

Die Jungens (und natürlich auch Damen)von ariva sind nicht von gestern.

Na dann
rm sind meine Namensinitialien
1512 ist mein Geburtsdatum